One vaccine is based on a yeast-derived (Pichia pastoris) recombinant protein comprised of the receptor-binding domain (RBD) of the SARS-CoV formulated on alum and referred to as the CoV RBD219-N1 Vaccine.
Our preliminary studies now show that the SARS-CoV-2 RBD candidate, which is specific for the sequence of the SARS-CoV-2, can also be highly produced in the yeast P. pastoris. Both approaches reinforce each other, as the processes developed for the CoV RBD219-N1 candidate also apply to the SARS-CoV-2 candidate, and both antigens downstream could be further developed as potentially a bivalent or a universal coronavirus vaccine.